Teleflex Incorporated (NYSE: TFX) — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the provided filing text does not provide clear standalone fourth-quarter results.
Business context
Teleflex is a global medical technology company, primarily selling single-use devices for hospital, healthcare-provider and surgical applications. It reports four segments: Americas, EMEA, Asia and OEM. Approximately 95% of revenue came from single-use medical devices.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Net revenue | $2,791.0 million | $2,809.6 million |
| Gross profit / margin | $1,531.1 million / 54.9% | $1,549.6 million / 55.2% |
| Income from continuing operations | $362.9 million | $485.1 million |
| Net income | $363.1 million | $485.4 million |
| Diluted EPS | $7.68 | $10.23 |
| Operating cash flow from continuing operations | $342.8 million | $652.1 million |
| Capital expenditures | $79.2 million | $71.6 million |
| Free cash flow (non-GAAP) | $263.6 million | $580.5 million |
| Cash and cash equivalents at year-end | $292.0 million | $445.1 million |
| Total debt, including debt issuance costs | $1,711.5 million | $1,850.1 million |
Gross margin was 54.9%; the filing does not present a single consolidated operating-margin figure in the cited results discussion. The effective income tax rate was 18.6%, versus 13.3%. Management said cash, operating cash flow and available revolving and receivables-securitization facilities should fund operating needs, capital spending and debt obligations for the next 12 months and foreseeable future. The company reported $1,431.3 million of net debt and a 26.2% net-debt-to-total-capital ratio. It was in compliance with debt covenants at year-end.
Material changes versus 2021
- Revenue decreased 0.7%. Higher sales of new products and price increases added $184.9 million, partially offset by lower existing-product volume, unfavorable foreign exchange and the respiratory-product divestiture.
- Gross margin declined 30 basis points, mainly from inflation in logistics, distribution, raw materials and labor, partly offset by price increases and favorable currency effects.
- Net income fell to $363.1 million from $485.4 million. The prior year included a $91.2 million gain on the respiratory-business sale, compared with a $6.5 million gain on sale of assets in 2022; 2021 also included a $13.0 million debt-extinguishment loss.
- Operating cash flow fell by $309.3 million, reflecting less favorable operating results and working-capital movements, including higher inventory and tax payments. Inventory rose to $578.5 million from $477.6 million.
- Segment revenue was mixed: Americas -0.3%, EMEA -8.0%, Asia +2.9% and OEM +11.0%. EMEA operating profit declined 55.2%, while Americas and OEM operating profit rose 6.6% and 16.3%, respectively.
Outlook, management commentary and notable items
- No full-year 2023 revenue or earnings guidance is provided in the supplied filing text. Management said inflation, supply-chain constraints, backorders, currency volatility and uneven procedure demand would continue to affect results, particularly in the near term; impact and duration were uncertain.
- A restructuring plan launched in November 2022 is expected to be substantially completed in 2023. Estimated charges are $39–$48 million, with annual pretax savings of $21–$23 million once fully implemented; most expected cash outlays are in 2023.
- The respiratory-divestiture manufacturing transition is expected to be completed by the end of 2023. Teleflex expects $15 million of additional proceeds from Medline if specified manufacturing assets are transferred.
- Teleflex acquired Standard Bariatrics for consideration valued at $211.8 million, including $38.8 million of estimated contingent consideration; milestone payments could total up to $130 million. A separate catheter-company asset acquisition cost $22.8 million initially, with up to $26.2 million of additional payments possible.
- Italian medical-device payback invoices for 2015–2018 are under appeal. Teleflex reserved $10.9 million; if enforced in its existing form, estimated payments could exceed the reserve by up to $23 million.
- Key risks include medical-device regulation and product liability, reimbursement and pricing pressure, reliance on suppliers and sterilization capacity, inflation and labor constraints, foreign exchange and interest-rate exposure, acquisition integration, and substantial indebtedness. A 1% change in variable rates would change annual interest expense by about $7.2 million based on year-end debt.
- The independent auditor issued an unqualified opinion and found internal control over financial reporting effective; Standard Bariatrics was excluded from the control assessment because of its recent acquisition and was less than 1% of consolidated revenue and assets, excluding goodwill and intangibles.
Most important facts for investors to verify
- Whether new-product growth and price increases can offset existing-product volume declines, foreign exchange and divestiture-related effects.
- Whether operating cash flow recovers as inventory and other working-capital pressures ease.
- Execution, total costs and realized savings from the 2022 restructuring and respiratory manufacturing transition.
- Outcome of the Italian payback appeals and any additional payment exposure; also monitor the unresolved potential China tariff penalties of $3–$20 million.
- Standard Bariatrics milestone performance and contingent payments, alongside debt service, refinancing and covenant headroom.